HomeACQUISITIONS and MERGERSIntegrity Implants and Fusion Robotics Merge to Form Accelus

Integrity Implants and Fusion Robotics Merge to Form Accelus

Integrity Implants Inc., a privately held medical device company focused on Adaptive Geometry™ technology designed to enable MIS spine surgery, and Fusion Robotics, LLC, a privately-held medical technology company focused on efficient and cost-effective navigation and robotic targeting solutions for spine surgery, today announced that they have consummated a merger combining the two companies. The combined company will be re-branded as “Accelus” and is uniquely positioned to accelerate the adoption of minimally invasive surgery as the standard of care in spine.

“Accelus will create opportunities for wide-scale adoption of robotics in spine surgery—both in hospitals and ambulatory surgery centers (ASCs)—by addressing previous constraints related to cost and efficiency,” said Chris Walsh, who will serve as the CEO of Accelus. “Both Fusion Robotics and Integrity Implants have built enabling technology platforms that create a force multiplier for spinal care. Our products and culture create accessibility to fit each patient’s anatomy, each surgeon’s preferred approach, and each healthcare facility’s space and budget limitations, embodying our core principle of access without compromise.”

Although the benefits of MIS have been recognized for decades, broad adoption in the spine market is still constrained relative to other orthopedic and interventional procedures. The combination of Fusion Robotics’ efficient, compact and scalable robot with Integrity Implant’s unique Adaptive Geometry implants will enable the rapid acceleration of MIS adoption.

“We believe Accelus is poised to be the next dominant player in the spine market,” said Alex Lukianov, who will serve as Chairman of the company’s Board of Directors. “Accelus will uniquely accelerate the penetration of MIS while fostering a culture of outstanding performance together with an unparalleled product development engine to continually simplify surgical procedures. Our growth prospects are tremendous. Onward and upward!”

Integrity Implants’ flagship FlareHawk® Lumbar Interbody Fusion Device received FDA clearance in 2016 and CE mark approval in 2021, and to date more than 10,500 FlareHawk devices have been implanted in more than 8,000 patients. Integrity Implants also holds FDA clearances for its LineSider® Spinal System, FlareHawk TiHawk™ Interbody Fusion System, and Toro™-L Interbody Fusion System. Fusion Robotics received a 510(k) clearance for its initial product offering and started performing spine procedures in the U.S. market earlier this year.

“This combination of teams and technology represents a transformative opportunity to accelerate innovation in spine,” said neurosurgeon Kevin Foley, M.D., Chief Robotics Officer of Fusion Robotics. “The implant portfolio is complementary to the robotics platform, and with the rapid strides we are making in robotics development—specifically related to our fluoroscopy-based robotics system—the synergies will become even more robust in the coming months.”

Accelus’ corporate office, R&D, distribution, and Accelus Clinical Education (ACE) surgeon training facility will be headquartered in Palm Beach Gardens, Fla. Additional ACE labs and R&D centers will be located in Boulder, Colo. and San Diego, Calif.

The company’s Executive Management Team will consist of leaders from both Integrity Implants and Fusion Robotics, who bring decades of experience and leadership across spine, navigation, and surgical robotics. Accelus’s Board of Directors will be composed of Fusion Robotics’ founders Alex Lukianov and Brad Clayton; Integrity Implants’ founders Chris Walsh and Wyatt Geist; and current Integrity Implants Directors Nate Ward, Ned Lipes, and Paul Birkmeyer.

“The organizational synergies go beyond products and technology, as we are pulling together the ‘A-team’ of spine,” Walsh added.

Accelus will be showcasing its current product portfolio during the 2021 Spine Summit meeting in San Diego this July and the 2021 Annual Scientific Meeting of the American Association of Neurological Surgeons in Orlando in August, as well as unveiling new product launches at the North American Spine Society’s 36th Annual Meeting in Boston this fall.

Medical Device News Magazinehttps://infomeddnews.com
Medical Device News Magazine is a division of PTM Healthcare Marketing, Inc. Pauline T. Mayer is the managing editor.

Stay Connected


Don't Miss

Mark Foster Joins Xenocor BOD

Foster is a versatile and visionary C-Suite executive who brings 20 years of general management and leadership experience from both venture-backed growth-stage organizations and world-class medical device companies

Hinge Health Acquires the Most Advanced Computer Vision Technology for Tracking Human Motion

CEO Daniel Perez explained, “We won’t stop investing in technology to deliver the most patient-centered digital clinic that improves member experience and outcomes while reducing costs. wrnch allows us to take a giant leap forward in all respects.”

Dale W Wood Congratulates the Huma Team on Raising $130 Million

Major health and technology companies across the world have committed upwards of $130 million to Huma Therapeutics, the health-tech company backed by Dale Ventures.

Rhaeos Awarded $4 Million NIH SBIR Grant

Under the NIH SBIR grant, Rhaeos will leverage their existing wireless sensor hardware to provide additional quantitative flow data to the clinician, giving insight into this currently inaccessible and highly relevant shunt performance metric.

Gynesonics Announces FDA Clearance of Next Generation Sonata System

“This clearance brings significant system improvements that expand the location of fibroids that can be treated while allowing the physician to control all aspects of the treatment from within the sterile field,” said Jiayu Chen, Ph.D. Vice President, Engineering and Advanced Technologies at Gynesonics.

Blackrock Neurotech Invests In Groundbreaking Auditory Nerve Implant With University Of Minnesota And MED-EL

The new investment will enable the development and translation of a new ANI through preclinical studies and later, a pilot clinical trial, where the ANI is then implanted in up to three deaf patients.

Jonathan Chapman: New President/CEO of Trividia Health

Chapman said, “I’m honored to join the Trividia team as President and CEO. This organization has a long history of leadership within the healthcare industry as a provider of accurate, accessible, and affordable point-of-care solutions for the management of diabetes.”

SOLOPASS® System (Bedside Neuro-Navigation Device) Receives FDA 510(k) Clearance

inTRAvent’s SOLOPASS® system brings simple, portable, bedside neuro-navigation into the intensive care unit.

By using this website you agree to accept Medical Device News Magazine Privacy Policy